Key Points
- Limited data exploring the utility of IABPs in shock without acute myocardial infarction exist.
- Counterpulsation pumps depend on native LV contractile function.
- Hemodynamic monitoring with a pulmonary artery catheter should help guide management of the cardiogenic shock patient.
- More studies are required to identify the optimal patient population and hemodynamic parameters best suited for IABP therapy.
CONFLICT OF INTEREST
NKK: Institutional grants and speaker/consulting honoraria for Abiomed, Abbott, Boston Scientific, Medtronic, and Maquet/Getinge. CSH reports no conflicts of interest to disclose.
REFERENCES
- 1Hsu S, Kambhampati S, Sciortino CM, Russell SD, Schulman SP. Predictors of intra-aortic balloon pump hemodynamic failure in non-acute myocardial infarction cardiogenic shock. Am Heart J. 2018; 199: 181-191.
- 2Sintek MA, Gdowski M, Lindman BR, et al. Intra-aortic balloon Counterpulsation in patients with chronic heart failure and cardiogenic shock: Clinical response and predictors of stabilization. J Card Fail. 2015; 21(11): 868-876.
- 3Annamalai SK, Buiten L, Esposito ML, et al. Acute hemodynamic effects of intra-aortic balloon Counterpulsation pumps in advanced heart failure. J Card Fail. 2017; 23(8): 606-614.
- 4Fried JA, Nair A, Takeda K, Clerkin K, Topkara VK, Masoumi A, Yuzefpolskaya M, Takayama H, Naka Y, Burkhoff D, Kirtane A, Dimitrios Karmpaliotis SM, Moses J, Colombo PC, Garan AR. Clinical and hemodynamic effects of intra-aortic balloon pump therapy in chronic heart failure patients with cardiogenic shock. J Heart Lung Transplant. 2018; S1053-2498(18): 31396-2. https://doi:10.1016/j.healun.2018.03.011. [Epub ahead of print] PubMed PMID: 29678608.
